STOCK TITAN

SI-BONE (SIBN) CFO reports RSU awards and tax-cover share sales

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

SI-BONE, Inc.’s Chief Financial Officer Anshul Maheshwari reported a mix of equity awards and related share sales. On February 16, 2026, he acquired a total of 107,992 shares of common stock through grants of restricted stock units, which vest over multi‑year periods based on time and total shareholder return performance.

On February 17, 2026, he sold 21,528 shares of common stock in multiple open‑market transactions at prices between $15.18 and $15.62. Footnotes state these sales were solely to cover tax withholding obligations from RSU vesting under a sell‑to‑cover arrangement and were not discretionary trades.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Maheshwari Anshul

(Last) (First) (Middle)
C/O SI-BONE, INC
471 EL CAMINO REAL, SUITE 101

(Street)
SANTA CLARA CA 95050

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SI-BONE, Inc. [ SIBN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/16/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/16/2026 A 80,994(1) A $0.00 260,996 D
Common Stock 02/16/2026 A 13,499(2) A $0.00 274,495 D
Common Stock 02/16/2026 A 13,499(2) A $0.00 287,994 D
Common Stock 02/17/2026 S(3) 1,279 D $15.3501(4) 286,715 D
Common Stock 02/17/2026 S(3) 11,104 D $15.3593(5) 275,611 D
Common Stock 02/17/2026 S(3) 2,189 D $15.2881(6) 273,422 D
Common Stock 02/17/2026 S(3) 3,065 D $15.4597(7) 270,357 D
Common Stock 02/17/2026 S(3) 3,891 D $15.4073(8) 266,466(9) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest over four years beginning on February 15, 2026, and will be released in quarterly installments, subject to the Reporting Person's continued service through each relevant vesting date.
2. Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest, if at all, over three years based on the Issuer's total shareholder return (TSR) as measured against the TSR of the company at the median of the range TSRs of a set of peer companies established by the Issuer as set forth in the grant.
3. The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
4. This transaction was executed in multiple trades at prices ranging from $15.18 USD to $15.54 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
5. This transaction was executed in multiple trades at prices ranging from $15.13 USD to $15.62 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
6. This transaction was executed in multiple trades at prices ranging from $15.14 USD to $15.52 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
7. This transaction was executed in multiple trades at prices ranging from $15.24 USD to $15.645 USD; the price reported above reflects the weighted average sale price.
8. This transaction was executed in multiple trades at prices ranging from $15.24 USD to $15.62 USD; the price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
9. Includes 200,237 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Remarks:
/s/ Michael Pisetsky, Attorney-in-Fact for Anshul Maheshwari 02/18/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did SI-BONE (SIBN) report for its CFO?

SI-BONE reported its CFO, Anshul Maheshwari, received restricted stock unit grants and sold shares to cover taxes. The filing shows equity awards on February 16, 2026, followed by tax-related share sales on February 17, 2026, rather than discretionary selling.

How many SI-BONE (SIBN) shares did the CFO sell in this Form 4?

The CFO sold 21,528 shares of SI-BONE common stock in multiple open-market transactions. According to the footnotes, these trades were executed solely to satisfy tax withholding obligations from restricted stock unit vesting through a structured sell-to-cover mechanism.

At what prices were the SI-BONE (SIBN) CFO’s shares sold?

The reported sales occurred in multiple trades at prices ranging from about $15.18 to $15.62 per share. The Form 4 lists weighted average sale prices and notes that detailed trade-level pricing is available to shareholders upon request from the company or regulators.

Were the SI-BONE (SIBN) CFO’s share sales discretionary trades?

No, the filing states the sales were required to cover tax withholding obligations related to restricted stock unit vesting. The transactions were executed as sell-to-cover trades, meaning they were structured for tax payments rather than voluntary stock sales by the executive.

What equity awards did the SI-BONE (SIBN) CFO receive?

The CFO received grants totaling 107,992 restricted stock units on February 16, 2026. Footnotes explain some units vest over four years with quarterly releases, while others vest over three years based on relative total shareholder return performance against a defined peer group.

How do the SI-BONE (SIBN) CFO’s RSUs vest over time?

One RSU grant vests over four years beginning February 15, 2026, with shares released quarterly, contingent on continued service. Another RSU grant may vest over three years based on SI-BONE’s total shareholder return versus a peer group, introducing a performance-based component.
Si-Bone

NASDAQ:SIBN

SIBN Rankings

SIBN Latest News

SIBN Latest SEC Filings

SIBN Stock Data

671.26M
39.46M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SANTA CLARA